Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer

Fig. 5

MIR22HG function in TGFβ pathway via competing interaction with SMAD2. a, Enriched signaling pathways by genes co-expressed with MIR22HG in COAD and READ. b, The scatter plots showing correlation between expression of MIR22HG and SMAD2 in COAD and READ. c, Top panels showing the RNA immunoprecipitation between SMAD2 and MIR22HG. Bottom barplot showing the relative expression of MIR22HG in anti-SMAD2 antibodies and IgG. d, Immunoblotting for SMAD2 levels in cells treated with over-expressing MIR22HG or shMIR22HG and cycloheximide for different times. e, Interaction between SMAD2 and SMAD4 in HCT116 cells transfected with MIR22HG siRNA or in LoVo cells infected with the lentivirus expressing MIR22HG

Back to article page

Molecular Cancer

ISSN: 1476-4598